Methodological recommendations of the Regulatory Agencies

被引:5
|
作者
Torres, Ferran
Calvo, Gonzalo
Pontes, Caridad
机构
[1] Univ Autonoma Barcelona, Lab Bioestadistica & Epidemiol, Barcelona 08025, Spain
[2] Hosp Clin Barcelona, Unitat Avaluacio Prevencio & Suport, Serv Farmacol Clin, Barcelona, Spain
[3] Agencia Espanola Med & Prod Sanitarios, Div Evaluacion Clin, Madrid, Spain
[4] Vita Cientifica SL, Dept Med, Barcelona, Spain
来源
MEDICINA CLINICA | 2005年 / 125卷
关键词
methodological issues; statistical issues; clinical trials; regulatory guidelines;
D O I
10.1016/S0025-7753(05)72213-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The suitability of new drugs for use in the general population in terms of risk and benefit is assessed by the health authorities through their drug agencies. These agencies regulate the entry of drugs on the market and their conditions for use according to strict criteria of quality, safety and efficacy. To preserve the principle of transparency, the requirements are previously published as guidelines, which are freely available on the Internet. All these guidelines have the following basic recommendations in common: (a) appropriate methodology for the objective, defined in detail a priori, (b) traceability, (c) verification of the appropriateness of the methodology applied, (d) justification of any deviation from the initial plan and (e) demonstration of the robustness of the results in distinct scenarios. Regulatory guidelines differ from other methodological references in their emphasis on the practical issues of the design and performance of studies, accepted methodological principles, and systems to ensure quality assurance in research. Although these requirements might not be universally applied to all types of research, the guidelines are freely available and are a good reference for the authorship, review and publication of clinical trials. The present article aims to review some of the guidelines that could be especially useful.
引用
收藏
页码:72 / 76
页数:5
相关论文
共 50 条
  • [1] Benchmarking health technology assessment agencies-methodological challenges and recommendations
    Wang, Ting
    Lipska, Iga
    McAuslane, Neil
    Liberti, Lawrence
    Hovels, Anke
    Leufkens, Hubert
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2020, 36 (04) : 332 - 348
  • [2] Regulatory agencies' recommendations for medicine information leaflets: Are they in line with research findings?
    Young, Amber
    Tordoff, June
    Smith, Alesha
    [J]. RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2018, 14 (02): : 196 - 202
  • [3] REGULATORY AGENCIES
    VERNON, WN
    [J]. AMERICAN BAR ASSOCIATION JOURNAL, 1981, 67 (OCT): : 1238 - &
  • [4] METHODOLOGICAL RECOMMENDATIONS
    Vercseg Ilona
    [J]. CIVIL SZEMLE, 2018, 15 (04): : 177 - 177
  • [5] European regulatory agencies
    Cricorian, Maritza
    [J]. INTERNATIONAL SPECTATOR, 2005, 40 (02): : 104 - 104
  • [6] Responsibilities of regulatory agencies
    Delaney, S
    [J]. BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE, 1997, 74 (02) : 220 - 226
  • [7] The financing of regulatory agencies
    Marette, S
    Crespi, JM
    [J]. JOURNAL OF REGULATORY ECONOMICS, 2005, 27 (01) : 95 - 113
  • [8] Controlling regulatory agencies
    Laegreid, Per
    Roness, Paul G.
    Rubecksen, Kristin
    [J]. SCANDINAVIAN POLITICAL STUDIES, 2008, 31 (01) : 1 - 26
  • [9] REGULATORY AGENCIES AND THEIR FUNCTIONS
    SURGENOR, DM
    [J]. VOX SANGUINIS, 1972, 23 (1-2) : 68 - &
  • [10] Role of regulatory agencies
    Epstein, Jay
    Seitz, Rainer
    Dhingra, Neelam
    Ganz, Peter R.
    Gharehbaghian, Ahmad
    Spindel, Renato
    Teo, Diana
    Reddy, Ravi
    [J]. BIOLOGICALS, 2009, 37 (02) : 94 - 102